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Summary
We studied the mode of action of the low molecular weight
heparin PK10169 and two of its constituent fractions: EMT 966
High Molecular Weight Fraction and EMT 967 Low Molecular
Weight Fraction.
EMT 966 like standard heparin, acts primarily on thrombin
formed and not on prothrombinase (S type heparin). In contrast
EMT 967 has no direct effect on thrombin. At high concentra-
tions, it inhibits the prothrombinase complex (P type heparin).
PK10169, that contains the two EMTs shows both activities:
antithrombin and antiprothrombinase (mixed type heparin).
The addition of increasing amounts of EMT 967 to a constant
amount of EMT 966 does not influence the breakdown constant
of endogenous thrombin which is determined by the concentra-
tion of EMT 966 only. This demonstrates the absence of competi-
tion for AT III between the two components of PK10169.
ln platelet rich plasma, EMT 966 inhibits and postpones
thrombin generation more efficiently than unfractionated hepa-
rin, probably because it is less sensitive to neutralization by
platelet components (platelet factor 4). Amounts of EMT 967
that hardly inhibit thrombin generation in platelet rich plasma
enhance the effect of EMT 966 probably by neutralizing platelet
factor 4.
Introduction
Recently we developed a method that enables us to estimate
the course of prothrombinase activity in clotting plasma (1). This
method allowed us to discern the existence of two different types
of heparin according to their different modes of action on
thrombin generation in plasma (2, 3). The S type heparins that,
like standard heparin, act mainly by thrombin scavenging and the
P type heparins that, like the AT III binding pentasaccharide (2,
3) are inactive towards thrombin but inhibit prothrombinase in
plasma. From preliminary experiments it appeared that PK10169
was neither an S or an P heparin, but showed intermediate
behaviour. It thus imported to know if this was due to an intrinsic
property of one species of heparin molecule or due to PK10169
being a mixture of S and P type heparins.
Furthermore, in platelet rich plasma (PRP) some heparins are
more susceptible to neutralization by platelet factor 4 than others.
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Again, we wanted to investigate whether a poorly active heparin
fraction could influence the action of an active fraction via platelet
factor 4 neutralization.
Materials and Methods
Materials
The chromogenic substrate for thrombin was H.D-Phe-Pip-Arg-pNA
(52238) from KABI, Sweden. Kaolin was "Kaolin l6ger" provided by
B L B Laboratoires du Bois de Boulogne (Putcaux-France) The hepa-
rins were supplied by Pharmuka Laboratories (France) PK10169 is
obtained by alkaline hydrolysis of the benzylic ester of heparin. According
to the manufacturer PK10169 is identical to the commercially availablc
Enoxaparin/Lovenox@ EMT 966 and EMT 967 are prepared by gcl
filtration of PK10169 on ultrogel AcA206 roughly one third of PK 10169
was in the EM 967 fraction and two thirds in EMT 966. The 4th
lnternational Standard for Heparin(4th l.S.H.) was from the National
Institute for Biological Standards and Control. The averagc molecular
weight, antifactor lla and antifactor Xa activities, given by the manufac-
turers are indicated in Thble 1. These activities were measured as
described inYinazzer and Woler (4).
Plasma
Blood from healthy donors was collected on 0 13 M trisodium citrate;
nine parts of blood to one part of citrate solution A first and a second
centrifugation were perfbrmed at 3,000 x g, at 15" C for 15 minutes. A
third centrifugation was done at 4'C, for t hour at 23,000 x g The
platelet free plasma thus obtained was stored at -80'C It was checked
that the clotting factors and the antiproteases were in the normal range.
Defibrinated plasma was obtained by mixing an aliquot of plasma with
l:50 volume of a reptilase solution, letting a clot form for 10 min at37" C
and keeping the clotted plasma at 0" C for 10 min. The fibrin formed was
discarded by centrifugation (10 min, 5,000 x g, 4' C) or by winding it on a
small plastic spatula. The concentration of factors II, VII, VIil, IX, X, XI
and XII did not significantly change by the reptilase treatment as has been
shown before (1).
Proteins
Rcptilase was obtained from Laboratoires Stago (Asnidres, France), a
solution was obtained according to the instructions of the manufacturer
Soybean trypsin inhibitor (batch No 43 F-800) was obtained from Sigma
(St. Louis, USA). Staphylocoagulase was obtained from Laboratoires
Stago (Asnidres, France) and preparcd according to the instructions of the
manufacturer Coagulation factors were purificd as indicated in Bdguin et
al. (3). Human AT III was prepared by polyethylenc glycol precipitation
and heparin-scpharose affinity chromatography (5) followed by ion-
exchangc chromatography to remove the heparin (6)
Determination of Prothrombinase Activity in Plasma
To 200 pl of defibrinated plasma is added 50 pl of 0 05 M Tiis-HCl,
0.1 M NaCl, 0 5 mg/ml ovalbumin, pH 7.35 containing heparin at the
desired concentration and incubated for -5 min at 37" C At zero time.
thrombin generation is started by the addition of 50 pl of a solution
containing 100 mM of CaCl2 and a trigger of coagulation For the extrinsic
system this is human brain thromboplastin, final dilution 1:240, for the
intrinsic system 1 pM phospholipid and 0 25 mg kaolin (final concentra-
tions). At intervals a 10 pt aliquot of the mixturc is sampled into a
disposablc plastic cuvette containing 0.465 pl of 0.05 M Tris-HCl, 0.1 M
NaCt, 20 mM EDTA, 0.5 mg ovalbumin/ml, pH 7 90 and 25 pl of 52238
(a mM) prewarmcd for at least 5 min at 37" C. After 120 seconds the
reaction in the cuvette is stopped by adding 300 pl of concentrated acetic
acid. The cuvcttes are read at 405 nm in a LKB Ultrospcc II spec-
trophotometer. The amidolytic activities in the plasma samples were
calculated fiom the O.D. r'eading and expressed as the equivalent
concentration of thrombin The generation of prothrombinase activity was
calculated from the amidolytic activity curvc with the aid of a computer
program as described previously (1). Briefly, the observed amidolytic
activity is the sum of thrombin activity and the activity of o2M-thrombin
complex The rate of thrombin generation at any momcnt is the sum of
two processes: a) the conversion of prothrombin into thrombin by
prothrombinase and b) the decay of thrombin by the action of plasma
protease inhibitors. The rate of inhibition of thrombin at any time can be
calculated from the concentration of thrombin at that moment and the
pseudo first order rate constant of inhibition of thrombin by antithrom-
bin III (k1) and o2-macroglobulin (k2). The rate of prothrombin activation
(prothrombinase activity) then can be calculated from the observed rate of
generation of amidolytic activity and the rate of thrombin inhibition
Determination of the Pseudo First Order Rate Constant of Inhibition
of Thrombin in Plasma
Defibrinated plasma (200 pl) was incubated with 24 pl of buffer
containing 0.05 M Tiis-HCl, 0.1 M NaCl, 0 5 mg ovalbumin/ml, pH 7 35
Thrombin generation was started as described in the previous section
Two minutes after the peak activity of thrombin, 10 pl of Soybean Tiypsin
Inhibitor (SBTI) solution (10 mg/ml) was added, together with 16 pl of
buffer that contained thc heparin to be testcd SBTI at this concentration
was shown to stop completely and instantaneously thc activity of
prothrombinase and not to influence the acti.vity of thrombin (1). At
suitable time intervals after addition of the SBTI solution, 10 pl aliquots
of the incubation mixturc were added to cuvettes to measure residual
thrombin activity as described The pseudo first order ratc constant of
inhibition of thrombin generatcd in plasma was calculated by fitting the
data to
C t : C n + C o e - ( k r + k ' ] ) t
wherc C, is the thrombin activity at time t, Cp is the steady endlevel
activity, C. + CR is the thrombin activity at the time of SBTI addition, k1
is the AT Ill-dependcnt decay constant of inhibition of thrombin, k2 is thc
decay constant of inhibition of thrombin by o2-macroglobulin (42-M). The
ratio of k1 to k2 is determined as the ratio of thc amounts of thrombin
complexed with AT III and n2-M as described before (1).
First order rate constants in plasma were obtained as indicated above.
In purified systems they were derived from the semi-logarithmic decay of
factor activity in the presence of AT III and heparin at the conccntration
indicated (Thbles 2 and 3).
The second order ratc constants were obtaincd from the tirst order rate
constants by dividing through the AT III-heparin concentration prevailing
in the experiments.
Results
Effect on the Decay of Thrombin Generated in Plasma
In Fig. 1 we see that with regard to their action on thrombin the
low molecular weight heparins (LMWH) appear in two groups:
those such as EMT 966 and PK10169 that, like standard heparin,
do increase the AT III dependent breakdown constant (k1) of
endogenous thrombin and EMT 967 that does not. It is seen that
there is a rectilinear relationship between the concentration of
heparin and the decay constant of thrombin for EMT 966,
PK10169 and standard heparin. From the slopes of these lines the
second order rate constants of thrombin inactivation in PPP can
be calculated (Table 2). These second order rate constants enable
us to compare the antithrombin activity in plasma of different
LMW heparin on a weight basis and their relation to the activity
of UFH.
In Table 2 they are also compared to the values found in a
purified system consisting in AT III (a00 nM), thrombin (20 nM)
and heparin (varying concentrations). The rate constants of
LMWH are considerably lower than those of standard heparin.
This is especially clear when the results are expressed on a molar
basis. The activity of heparins in plasma is about 15-35% of that
observed in a purified system. This can be attributed to the lower
susceptibility of endogenous thrombin to AT Ill(-heparin) action
and/or to the presence of heparin binding proteins in plasma.
In Thble 3 we summarize the data on the breakdown constants
of factor IIu, IXo, X,, and XIo in purified systems. The activity of
heparins decreases in the order llu, Xo, IXo and XIu. The
exception is EMT 967 that has no activity towards thrombin.
In order to see whether EMT 967 competes with EMT 966 for
AT III under our experimental circumstances, we added increas-
ing amounts of EMT 967 to a fixed amount of EMT 966, it did not
cause any significant change in the activity of the EMT 966
(F ig .2 ) .
Influence of LMW Heparins on the Thrombin Generation
in Plasma
The formation of thrombin in plasma was measured in the
presence and absence of PK10169, EMT 966 and EMT 96'7,both
Table I Characteristics of the heparins studied
Mean molecular
weight
(range)
Heparins Anti IIa
activity
(U/mg)
Anti Xa
actlvlty
(U/mg)
4th  I .S  H
PK10169
EMT 966
EM'I 967
14 (3-18)
4.s (2-e)
6.s (s-e)
3.3 (2-4)
194
30
70
0
t94
t20
160
10
The anti II^ and anti Xu activities were estimated according to (4)
Table 2 The second order rate constants of the inactivation of thrombin
for heparins
A) k (min-r  .  t t5t  'ml)  B) k (min- l  .nM-l  .ml)
Heparin Purified Plasma Purified Plasma
4 t h  I . S . H
PK10169
EMT 966
EMT 967
< / a
-f-)
96.2
0
3 8 7
7 . 3
14.8
0
8.57
1 . 1 1
l .  t 4
0.05
r20 4.5
5 6.5
3 3 3
0 .16  0
In section A the data are on weight basis, in section B they are calculated
on basis of the molar concentration, using the molecular weights from
Thble 1.
R : Ratio of the rate constant in a purified system over that in plasma
Table 3 The second order breakdown constants of various ciotting
proteases with heparins in a purified system
Hepar in ITa IXa XIa
0.021,
0.002
0.006
0.001
k is expressed in min I '
Experimental conditions :
a) AT III: 400 nM; II":
b) AT III: 400 nM; IXu:
c) AT III: 400 nM; Xu:
d) AT III: 400 nM; XIo:
p g  -  ' m l
20 nM: heparin: 0-300 ng/ml
80 nM; heparin: 0-1 pg/ml
20 nM: heparin: 0-300 ng/ml
4 nM; heparin: 0-5 pg/ml
Xa
4th I.  S. H.
PK10169
EMT 966
EMT 967
0.180
0.109
0 .158
0.020
3 8 7
7 3
1 4 8
0
4 I
0 .8
1 .3
0 .4
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=200
E
co
=
o
ccl 00
I
F
\+
E
Y
o  1vg /m t  2
Hepa r i n
Fig.1 The AI Ill-dependent pseudo first order rate constant of throm-
bin decay in thromboplastin activated plasma as a function of the heparin
concentration. I EMT 966; A PK10169; O EMT 967
5
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Flg.3 The effect of PK10169 on the thrombin generation induced by
thromboplastin (curves A, B, C) or by contact activation and phos-
pholipids (curves D, E, F) A and D: no heparin; B and E: 0 6 pg/ml;
C and F: 1,.2 pglml
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Fig 2 Influence of the addition of increasing amounts of EMT 967 on
the thrombin decay constant of a fixed concentration of EMT 966. O no
EMT 966; O 0.3 pg/ml EMT 966
T l M E t u t i n l  
1 0
Fig 4 The effect of EMT 966 on the thrombin generation induced by
thromboplastin or by contact activation and phospholipids Legends as in
Fis.2
1.20.9u.b
in the extrinsic system using thromboplastin as a trigger and in the
intrinsic system using kaolin and phospholipid as a trigger.
Because EM'f 967 is partially adsorbed onto kaolin at the usual
concentration of 25 pglml of kaolin we used 2.5 p.glml. This still
ensures normal contact activation but heparin adsorption is
negligible.
As shown in Fig. 3, 0.6 pg/ml and 1.2 pg/ml of PK10169 inhibit
respectively 50% and 68% of the thrombin burst via the extrinsic
pathway and 40"h and 58% of thrombin in intrinsic pathway.
In Fig.4 we can see that 0.2 pglml and 0.6 pg/ml of EMT 966
inhibit respectively 31% andT2Yo in the extrinsic system and 44"h
and 74Yo in the intrinsic system. Fll^l 967 proves much less
active. It was necessary to increase its concentration up to 5 pg/ml
to obtain significant inhibition.
The question now arises whether the inhibition of the thrombin
burst is due to inhibition of prothrombin activation or to increased
thrombin decay.
- )L
Influence of LMW Heparins on the Prothrombinase Activity
in Plasma
Using the pseudo first order rate constants of inhibition of
thrombin by antithrombin III (k1) expressed in Fig. 1 and the
value of 0.23 for the decay constant of thrombin (k2) due to o2-
macroglobulin (1), we calculated the prothrombinase activity
from the thrombin generation curves.
The data are shown in Thble 4. In the extrinsic pathway,
EMT 966 causes its inhibition by thrombin scavenging without
inducing an important inhibition of prothrombinase in the extrin-
sic system. If thus acts exactly like standard heparin (2) , EI|I4T 967
is different. Only at high concentrations it inhibits the thrombin
peak, this inhibition must be attributed to the inhibition of
prothrombinase or to a decreased prothrombinase generation
because there is no influence on thrombin decay. PK10169
appears to inhibit by increased scavenging of thrombin as well as
by prothrombinase inhibition (Thble a, Fig.5).
Thble 4 Summary of the inhibitions observed via the extrinsic and intrinsic pathways
Conc.
(pg/ml)
EMT 966
Extr
Thr. P.ase
EMT 967
Extr. Intr
Pase Pase
PK10169
Extr.
Thr. Pase
Intr,
Thr P ase
Intr.
Thr P.ase
0.05
0.20
0.30
0.35
0.60
L . 2
5
10
t2
3'7
s9
62
72
87
,7
8
10
72
18
20
l7
44
68
95
13
20
r'7
53 l 1
53
81
10
30
62
L3
26
50
68
85
20
t9
28
/ a
4)
76
23
40
58
80
5
9
18
26
37
The inhibitions are expressed in 7" of an uninhibited control run in parallel
Thr. : Thrombin: Pase: Prothrombinase
Influence of LMWH on Thrombin Generation
in Platelet-Rich Plasma
In an attempt to investigate the action of our LMW heparins in
a situation nearer to the in vivo circumstances we measured
thrombin generation in platelet rich plasma (PRP).
As previously found for unfractionated heparin (2, 7) we
observed that PK10169 induces a prolongation of the lag phase
before the appearance of the thrombin burst. Contrary to
standard heparin, PK10169 inhibits also the peak of thrombin as
shown in Fig.6. One of the subfractions of PK10169, EMT 966
has the same behaviour but EMT 967 is hardly efficient in the
range of concentrat ions that is present in PK10169 (Fig.6).
Discussion
We have described before tlrat neither unfractionated heparin
nor a number of LMW heparins seem to cause a significant
inhibition of prothrombinase in plasma clotting via the extrinsic
pathway (2). This was a surprising finding in view of the fact that
conventionally measured anti Xo activities of LMWHs, when
compared to that of UFH, are higher then the respective
antithrombin activities. In fact, the only LMWHs that inhibit
prothrombinase activity to a significant extent without influencing
thrombin breakdown were those that, like the Choay pen-
tasaccharide, do not show antithrombin activity We therefore
proposed the existence of two classes of heparin, those active
against thrombin but hardly against prothrombinase (S heparin)
and those inactive against thrombin but active against prothrom-
b inase (P  hepar in )  (2 ,  3 ) .
In this article we describe that PK10169. a LMWH with a mean
molecular weight of 4,500 daltons does inhibit prothrombinase
but also increases the AT III dependent breakdown of thrombin
in plasma. This raises the question of whether there exist heparins
of a mixed P & S type. Alternatively preparations that show a
mixed type behaviour may indeed be mixtures of P type and
S type molecules.
We separated PK10169 in a high (6.5 kDa) and a lower
(3 kDa) molecular weight fraction The low molecular weight
fract ion (EMT967) showed a pure P type behaviour, i .e. no
thrombin inhibition but a persistent antiprothrombinase activity
at relatively high concentration (>5 pg/ml) The higher molecular
weight fraction (EMT 966) obtained the characteristics of an S
type heparin, i.e. persistent antithrombin activity and low anti-
prothrombinase activity. It appears therefore more likely than not
that the mixed type behaviour of PK10169 is due to its being a
mixture of P and S type heparins. It must be noticed however,
that whereas P type heparins (i. e. pentasaccharide and EMT 967)
have no antithrombin activity, S type heparins always have a
residual antiprothrombinase activity that shows up at higher
concentrations. This can partly be attributed to inhibition of the
positive feedback reactions, i. e. the activation of factor V and
VIIL AIso these preparations may always be contaminated by P
type heparins. It cannot be excluded, however, that S type
heparins have an inherent antiprothrombinase activity that is
obscured by the far more outspoken antithrombin activity.
'=
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Flg.5 The effect of PK10169 on prothrombinase activity. Prothrombi-
nase activities, were calculated from the thrombin generation curves
shown in Fig.3. Legends as in Fig 3
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Flg.6 Influence of EMT 966, EMT 967, recombined PK10169 on the
thrombin generation in platelet rich plasma in the presence of traces of
thromboplastin (112400 final dilution) O No heparin; A 1 3 pgiml
EMT966; O 0.7 pg/m1 EMT96'7;  |  4p+glml PK10169: A 1.3 pglml
EMT 966 + 0 7 pLg EMT 967
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The differences of the mode of action of LMWHs on isolated
factors, even when added back to plasma as in the conventional
anti IIu and anti Xu tests, and on factors generating in clotting
plasma remain intriguing. At the moment we cannot offer an
explanation.
If in PPP, within the group of S type heparins, there is no
difference in the mode of action of UFH and LMWH, an
important difference appears as soon as PRP is tested. We have
shown before that up to 0.5 U/ml of UFH is practically com-
pletely inactivated by activated platelets. This makes that UFH in
PRP postpones the thrombin burst but hardly inhibits it (7). As
we can see from Fig. 6. PK10169 and EMT 966 both postpone and
inhibit the generation of thrombin in PRP. Preliminary experi-
ments suggest that this is due to a lower suceptibility of LMWHs
to pf4. This is in good accordance with observations showing pf4
susceptibility to decrease with decreasing molecular weight
18-12).
In Fig.6 is seen that EMT 967, when added in a concentration
of 0.7 pg/ml does not significantly inhibit thrombin generation in
PRP. When the same amount is added to 1.4 pg/ml of EMT 966 it
enhances the inhibition caused by EMT 966. The likely explana-
tion is that F.MT 967 binds to pf4 and neutralizes it so that more
EMT 966 is left in free form. This may be an example of a general
mechanism by which LMWHs that in itself are inactive may, in
PRP, potentiate the action of active heparin components.
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